The present study investigated the ability of surfactant associated protein A1 (SFTPA1), a major component of lung surfactant, to bind and serve as a signal in human cultured myometrial cells. By using ligand blot analysis with 125I-SFTPA1, we consistently identified two myometrial SFTPA1 interacting proteins (55 and 200 kDa). We found that the SFTPA1 immunoreactive protein was present in myometrial cells. We also showed by indirect immunofluorescence the nuclear translocation of RELA (also known as NFkappaB p65 subunit) after activation of myometrial cells by SFTPA1. Neutralization of TLR4 did not reverse this effect. Moreover, SFTPA1 rapidly activated mitogen-activated protein kinase 1/3 (MAPK1/3) and protein kinase C zeta (PRKCZ). The prolonged treatment of myometrial cells with SFTPA1 upregulated PTGS2 (COX2) protein levels. We next evaluated whether SFTPA1 affected the actin dynamic. Stimulation of myometrial cells with SFTPA1 markedly enhanced the intensity of the filamentousactin pool stained with fluorescein isothiocyanate-phalloidin. Inhibition of PRKC or Rho-associated, coiled-coil containing protein kinase 1 (ROCK) reduced the SFTPA1-mediated stress fiber formation. Our data support the hypothesis that human myometrial cells express functional SFTPA1 binding sites and respond to SFTPA1 to initiate activation of signaling events related to human parturition. mechanisms of hormone action, myometrium, signal transduction, surfactant protein A, pregnancy, parturition, uterus
INTRODUCTION
During pregnancy, the quiescence of the uterine smooth muscle is essential for the support and accommodation of fetal growth. The reversal of this quiescence leads to parturition. The control of the onset of labor in women is as yet unknown because of the multiplicity of factors involved (hormonal, mechanical, genetic, and/or environmental). Understanding these mechanisms is of great importance because spontaneous preterm deliveries (before 37 completed weeks of gestation) account for approximately 6% to 12% of all births in western countries and constitute the major causes for neonatal mortality (reviewed in [1] ). Modulation of the immune/inflammatory mechanisms is now widely accepted at the time of parturition. Indeed, at the end of pregnancy, leukocytes invade uterine tissues concomitantly with an increased production of proinflammatory cytokines, chiefly tumor necrosis factor (TNF) superfamily, member 2) formerly tumor necrosis factor alpha, interleukin 1 beta (IL1B), and interleukin 6 (IL6), at the fetomaternal interface. Such inflammatory response can be initiated prematurely by a maternal ascending infection. The cytokine-mediated inflammatory process is directly involved in the release of uterotonic agents (reviewed in [1] ). One classical example is the up-regulation of prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), PTGS2 (also termed cyclooxygenase 2) [2] and prostaglandin production, which have been shown to induce cervical ripening [3] , myometrial contractions [4, 5] , and rupture of the fetal membranes [6] , leading to delivery and birth [7] . Another clue is that the initiating signal for parturition may arise from the fetal lung. Condon et al. [8] have described surfactant protein A (SFTPA1, also known as SP-A) as a link between fetal lung development and the timing of labor in the mouse. The hypothesis was that SFTPA1 secreted by the fetal lung into amniotic fluid after Day 17 of gestation activates fetal amniotic fluid macrophages, leading to their migration to the maternal uterus, where they activate RELA (also called nuclear factor kappa B, NFkappaB), resulting in an increase in uterine contractility and parturition. SFTPA1 was detected in the amniotic fluid at Week 19 of human gestation and increased dramatically in the third trimester of pregnancy [9] . However, the model reported in mice [8] does not seem to be extrapolated to humans. Indeed, in light of two recent studies by Kim et al. [10] and Leong et al. [11] , no macrophage of fetal origin was observed in the human myometrium at term. From these observations, the process by which SFTPA1 participates in the initiation of human parturition remains unclear.
The major sites of SFTPA1 synthesis and secretion are the alveolar epithelial type II cells and the Clara cells [12] , but growing evidence now shows that SFTPA1 expression is not restricted to the lung. SFTPA1 has been detected in uterine duct lumina of mouse [13] , in uterine tissues of mares [14] , and recently in rat myometrium at the end of gestation [15] .
SFTPA1 is a multifunctional protein capable of binding several ligands, including phospholipids, carbohydrates, and calcium. SFTPA1 belongs to the calcium-dependent lectin family known as collectins that mediate a variety of immune cell functions (reviewed in [16] ). SFTPA1 can bind bacterial lipopolysaccharide (LPS) and modulate LPS-elicited responses through interactions with components of the LPS receptor complex, like the toll-like receptor 4 (TLR4) or CD14 [17, 18] , but SFTPA1 can also act independently of the LPS signaling pathway [19] . In macrophages, activation of TLR4 by LPS initiates a cascade that culminates with the activation of RELA and the subsequent production of proinflammatory cytokines [20] . We have previously demonstrated that cultured human myometrial cells express TLR4, and cell exposure to LPS, a strong inducer of labor in pathologic conditions, leads to protein kinase C zeta (PRKCZ) activation associated with nuclear translocation of RELA (the p65 subunit of NFkappaB) [21] .
Recent data provided the first evidence for a direct effect of SFTPA1 on rat myometrial cells. Indeed, SFTPA1 bound to its cognate-specific binding sites led to the activation of the mitogen-activated protein kinases, including the p42 and p44 kinases (also called MAPK1/3) and the induction of PTGS2 expression. A negative cross talk between LPS and SFTPA1 signals has also been described [15] .
In the present study, we addressed the question of whether SFTPA1 may directly regulate human myometrial cell functions. After demonstrating the presence of SFTPA1 in cultured human myometrial cells, we first hypothesized that SFTPA1 binding to myometrial cells can affect the translocation of RELA and explored whether such an SFTPA1 effect implicates the TLR4 receptor. We then investigated the influence of SFTPA1 on the well-characterized signaling modulators of uterine contractility during pregnancy and labor such as MAPK1/3, PRKCZ, and PTGS2. We also evaluated whether SFTPA1 affects Rho signaling in order to modify the actin dynamic, a key determinant of uterine contractility.
MATERIALS AND METHODS

Chemicals
Dulbecco Modified Eagle Medium (DMEM), trypsin-EDTA, penicillinstreptomycin mixture, and phosphate-buffered saline (PBS) with and without calcium and fetal calf serum (FCS) were obtained from Invitrogen Life Technologies (Cergy-Pontoise, France). Lipopolysaccharide from Escherichia coli 127:B8 was obtained from Sigma-Aldrich (St. Louis, MO). Sodium I 125 (0.78 MBq/ll) was purchased from ICN Biomedical, Inc. (Irvine, CA). Electrophoresis reagents were obtained from Bio-Rad (Richmond, CA). Hybond-P membranes, enhanced chemiluminescence detection system (ECL) and x-ray film were obtained from Amersham International (Chalfont, Buckinghamshire, UK). Inhibitors of PRKC (Ro318220) and of Rhoassociated, coiled-coil containing protein kinase 1 (ROCK) (Y-27632) were purchased from Calbiochem (La Jolla, CA). Rabbit antibody against PRKCZ was from Sigma-Aldrich. The anti-active MAPK1/3 antibody was obtained from Promega (Madison, WI). Specific antibodies for SFTPA1, RELA ACTB (also known as beta-actin), and MAPK1 were purchased from Santa Cruz Biotechnology (Tebu-Bio, France). Functional grade purified anti-human TLR4 (HTA 125) was from Bioscience (Cliniscience, Montrouge, France). The Alexa Fluor R 488 donkey anti-rabbit IgG was from Interchim (Montluçon, France). Fluorescent mounting medium was obtained from DAKO (Carpinteria, CA). The protease inhibitor cocktail (P-2714), leupeptin, Nonidet-P40, phenylmethylsulfonyl fluoride (PMSF), and other drugs and chemicals used were of the highest quality available from Sigma-Aldrich.
Isolation of SFTPA1
Native human SFTPA1 was purified from the bronchoalveolar lavage fluids of patients with alveolar proteinosis by sequential butanol and octyl glucoside extractions [22] as previously described [15] . The content of endotoxin in SFTPA1 preparations was estimated by Limulus Amebocyte Lysate method (BioWhittaker, Emerainville, France) and was 0.12 pg/lg protein.
Biological Samples
Myometrial tissues were obtained from pregnant women who delivered by elective cesarean section performed before the onset of labor (range 38.5-40 wk of gestation) because of a diagnosis of cephalopelvic disproportion. Myometrial strips were taken from the upper edge of the hysterotomy in the transverse lower uterine segment. Biopsies from the outer uterine wall at an extraplacental site were removed by sharp dissection, leaving behind the decidua. Patient consent and ethical approval were obtained in accordance with the Comité Consultatif de Protection des Personnes pour la Recherche Biomédicale (Paris-Cochin, France).
Myometrial Cell Culture
After collection, the myometrial biopsies were carefully minced with fine scissors before rapid transfer in DMEM supplemented with 100 U/ml of penicillin and 100 lg/ml of streptomycin. Human myometrial cells were obtained by the explant method, as described previously [23] . Cells were cultured in DMEM supplemented with antibiotic solution and 10% FCS, and routinely passaged when 90%-95% of cells were confluent. Confluent myometrial cells were identified by their typical ''hill and valley'' microscopic appearance and by their positive reaction to a monoclonal antibody raised against ACTA2 (also known as smooth muscle alpha-actin). The experiments presented in this study were performed with cells between their third to fifth passages, with no noticeable difference between results obtained with cells from individual passages and with cells obtained from different uteri. Each population of myometrial cells studied has been taken from a different patient.
Cell Stimulation
Confluent myometrial cells were incubated for 3 days in serum-free medium to achieve quiescence. Then, cells were either incubated without (control) or with SFTPA1 (5-30 lg/ml) or 10 lg/ml LPS for the indicated times. After treatment, cells were lysed on ice and scraped into ice-cold buffer A: 50 mM NaCl, 25 mM Hepes, pH 7.6, 10% glycerol, 1% Nonidet NP40, 50 mM NaF, 30 mM Na 4 P 2 O 7 , 5 mM Na 3 VO 4 , and protease inhibitor cocktail (2 mM 4-(2-aminoethyl) benzene sulfonyl fluoride, 1 mM EDTA, 130 lM bestatin, 14 lM E-64, 1 lM leupeptin, and 0.3 lM aprotinin). The lysates were subsequently centrifuged at 10 000 3 g for 15 min at 48C, and the supernatants were immediately frozen and stored at À808C until use. For the preparation of membrane fractions, serum-starved myometrial cells were scraped into an icecold buffer (10 mM Tris-HCl, 0.5 mM EDTA, 250 mM sucrose, 10 lg/ml aprotinin, 10 lg/ml leupeptin, and 1 mM PMSF) and then homogenized. The resulting homogenates were centrifuged for 5 min at 700 3 g. The supernatants then were ultracentrifuged for 20 min at 100 000 3 g. The resulting pellets were suspended in lysis buffer and constituted the membrane fractions. In some experiments, myometrial tissue was homogenized (200 mg/ml) in ice-cold buffer A with an Ultra-turrax apparatus (IKA-WERKE, VWR, Strasbourg, France) and centrifuged at 10 000 3 g for 20 min at 48C. The protein concentrations were determined by the method of Bradford using bovine serum albumin as standard.
Cell Viability and Morphological Features
Representative cell populations from each condition were examined under light microscopy. No significant change was noted under any condition. Viable cells were classified as those that were adherent and displayed Trypan blue exclusion.
Autoradiography of SFTPA1 Binding Proteins Using 125I-SFTPA1
Radioiodinated SFTPA1 was prepared by the iodogen method of Greenwood et al. [24] as previously described [15] . The purity of the preparation was assessed by SDS-PAGE and autoradiography. The specific activity of the 125I-labeled SFTPA1 was 8.4 3 10 6 cpm/lg protein. Quiescent myometrial cells were lysed and scraped into a lysis buffer consisting of 1% CHAPS in 50 mM Tris (pH 7.5), 300 mM NaCl, 5 mM Na 3 VO 4 , and the protease inhibitor cocktail. The extracts were centrifuged at 12 000 3 g for 20 min at 48C. Detergent-extracted proteins were separated by SDS-PAGE on 8% polyacrylamide gels and transferred onto a nitrocellulose membrane. Nonspecific binding sites were blocked by incubation for 1 h with 2% BSA in TS, which consisted of 5 mM Tris and 150 mM NaCl (pH 7.4). Blots were washed with 0.1% Tween-20 in TS and incubated overnight at 48C in TS with 0.2% BSA and 2 mM calcium supplemented with 125I-SFTPA1 (2.4 3 10 6 cpm) in the absence or presence of unlabeled SFTPA1 (50 lg/ml). Blots were thoroughly washed with 0.1% Tween-20 in TS containing 2mM calcium, dried, and placed against x-ray film for autoradiography (Hyperfilm, Amersham Biosciences, Saclay, France).
Immunofluorescence Analysis
Subconfluent myometrial cells were cultured for 2 days in 24-well dishes on coverslips as previously described [21] . Cells were then transferred to serum-deprived media for 72 h to achieve quiescence. Quiescent cells were incubated with 20 lg/ml SFTPA1 or with 10 lg/ml LPS in serum-free medium at 378C. For TLR4 blocking experiments, cells were incubated with neutralizing anti-TLR4 antibody for 60 min prior to addition of SFTPA1 or LPS. After fixation for 15 min with 4% paraformaldehyde in PBS, cells were rendered permeable by incubation in 0.1% Triton X-100 in 10% FCS-PBS for 15 min. They were incubated with the antibody directed against RELA (dilution 1:200) for 90 min and with the second Alexa Fluor R 488 donkey anti-SFTPA1 AND HUMAN MYOMETRIAL CELLS rabbit IgG fluorescein isothiocyanate (FITC)-labeled solution (dilution 1:500) for 45 min. Filamentous actin pools (F-actin) were stained with FITC-labeled phalloidin (1 lg/ml) in 0.1% Triton X-100 in 10% FCS-PBS for 30 min at room temperature protected from light. When PRKC or ROCK inhibitors were used, myometrial cells were exposed for 45 min to one of these drugs at the appropriate concentration and then to SFTPA1. Nuclei were labeled with Hoechst 33342, diluted 1:500 in water, for 2 min. Coverslips were mounted on slides using fluorescent mounting medium. A Nikon E-600 inverted microscope was used for conventional fluorescence microscopy, and photographs were taken using Coolsnap Software (RS Photometrics, Evry, France). Negative controls were carried out by omitting the primary antibody.
Western-Blot Analysis
Equal amounts of protein lysates were separated by SDS-PAGE on 10% gels and transferred onto a nitrocellulose membrane. Nonspecific binding sites were blocked by incubating the membranes with 5% low-fat dried milk in TBST (10 mM Tris HCl, pH 7.5, 0.15 M NaCl, 0.1% Tween 20). The membranes were then incubated overnight at 48C in TBST/1% milk with the indicated antibodies at the appropriate concentrations: SFTPA1 (1:1000), PRKCZ (1:5000), p-MAPK1/3 (1:5000), or PTGS2 (1:1000). Membranes were washed with TBST and incubated with either donkey anti-rabbit or anti-mouse secondary antibody conjugated with horseradish peroxidase. The blots were developed with ECL reagents and visualized on Kodak x-ray films. Molecular weight markers were run in parallel.
For standardization, the membranes were stripped with a buffer that contained 62.5 mM Tris (pH 6.2), 2% sodium dodecyl sulfate, and 100 mM beta-mercaptoethanol at 508C for 30 min and reprobed with polyclonal antibody raised against ACTB or against total MAPK1. Densitometric analysis was performed using the National Institutes of Health Image J software [25] .
Statistical Analysis
All the bands shown are from one representative experiment, and all densitometric data are the mean 6 SEM of four independent experiments. Statistical significance was determined using one-way ANOVA, followed by post hoc tests with Stat View software (SAS Institute, Cary, NC). Values of P , 0.05 were considered statistically significant.
RESULTS
Presence of SFTPA1 in the Human Pregnant Myometrium
Extracts prepared from human term myometrial tissue and from cultured myometrial cells were subjected to SDS-PAGE, and the presence of SFTPA1 was determined by Western blot. As shown in Figure 1 , a protein of the predicted size (approximately 36 kDa) was detected in myometrial tissue, cultured cells, and in immature rat lung (used as a positive control).
Detection of SFTPA1 Binding Sites by Ligand Blot
We assessed the ability of 125I-SFTPA1 to bind to myometrial cell proteins. As observed in Figure 2 , 125I-SFTPA1 bound two proteins of approximately 55 and 200 kDa. The 200-kDa SFTPA1 binding protein also was detected in protein extracts from the macrophage-like cell line U937, used as a positive control [15, 26] (data not shown). Competition studies showed that the binding of SFTPA1 to myometrial cell protein preparations was specific, as the two bands of 55 and 200 kDa were not detected when blots were incubated with labeled 125I-SFTPA1 in the presence of an excess of unlabeled SFTPA1 (50 lg/ml).
SFTPA1 Affects the Nuclear Translocation of RELA
The effect of SFTPA1 on NFkappaB activation was evaluated by its ability to induce the translocation of the RELA into the nucleus of myometrial cells. As shown in Figure 3 , RELA immunoreactivity was entirely absent from the nucleus of untreated cells, and it was evenly distributed throughout the cytoplasm. Incubation with 20 lg/ml SFTPA1 resulted in RELA accumulation in nuclei of myometrial cells after 5 min of treatment. The nuclear RELA staining reached a maximum at about 10 minutes and then slowly declined.
In parallel, we confirmed that LPS was able to translocate RELA via TLR4 in myometrial cells [21] . An anti-TLR4 neutralizing antibody blocked the LPS-induced nuclear translocation of RELA. By contrast, the anti-TLR4 antibody, used in the same conditions, failed to prevent the SFTPA1-mediated nuclear translocation of RELA.
SFTPA1-Induced Phosphorylation of MAPK1/3
To investigate whether SFTPA1 can stimulate MAPK1/3 activation, the phosphorylation status of MAPK1/3 was determined by using antibody to site-specific phosphorylated (i.e., active) forms of MAPK1 (42 kDa) and MAPK3 (44 kDa). As shown in Figure 4 , there was a discrete phosphorylation of MAPK1 in resting cells. Time-dependent experiments revealed that SFTPA1 (20 lg/ml) stimulation resulted in a rapid phosphorylation of MAPK1/3. The change in phosphorylation of MAPK1/3 was observed as early as 2 min and peaked at 10 min. The MAPK1/3 activation was also concentrationdependent. A consistent observation was that MAPK1 phosphorylation was always more pronounced that phosphorylation of MAPK3.
SFTPA1-Induced Activation of PRKCZ
The translocation of PRKC isoform from the cytosol to the membrane is considered as a determinant step of PRKC activation. To evaluate a role for PRKCZ in SFTPA1 signaling in myometrial cells, we examined the expression of PRKCZ by Western blot analysis in membrane fraction of cells following SFTPA1 treatment. As seen in Figure 5 , in the membrane fraction of myometrial cells, PRKCZ appeared as a doublet with estimated molecular weights of 76-80 kDa and treatment by 20 lg/ml SFTPA1 for 20 min elicited a significant increase in the level of both PRKCZ immunoreactive bands. SFTPA1 also induced a dose-dependent increase in membrane-bound PRKCZ.
SFTPA1 Upregulates PTGS2 Level
Because PTGS2, an enzyme upregulated by MAPK1/3, plays an important role in normal labor at term [27] , we evaluated the ability of SFTPA1 to induce PTGS2 protein in myometrial cells. As shown in Figure 6 , quiescent cells exhibited low basal PTGS2 expression. The presence of 20 lg/ FIG. 3. SFTPA1 induces RELA subunit translocation in nucleus of myometrial cells. Myometrial cells were grown on coverslips, serum starved for 72 h, and treated without or with 20 lg/ml SFTPA1 for the indicated times. For TLR4 blocking experiments, cells were pretreated for 45 min with 3 lg/ml neutralizing anti-TLR4 antibody and then were cultured without (control) or with 20 lg/ml SFTPA1 for 10 min or with 10 lg/ml LPS for 120 min. Cells were fixed, permeabilized, and immunostained with antibody against RELA followed by anti-rabbit FITC. The figure is representative of at least three independent experiments. Original magnification 3400.
FIG. 4. Activation of MAPK1/3 by SFTPA1 in myometrial cells.
Myometrial cells were incubated without or with 20 lg/ml SFTPA1 for the indicated times or were incubated for 5 min in the presence of increasing concentrations of SFTPA1. Reactions were stopped by adding cold lysis buffer, and detergent-extracted proteins (30 lg) were analyzed by SDS-PAGE in a 10% polyacrylamide gel. Immunoblotting was carried out with an anti-active MAPK1/3 antibody. The blot was then stripped and reprobed with anti-total MAPK1 antibody. Phosphorylated MAPK1 and total MAPK1 were semiquantified. The level of MAPK1 phosphorylation was normalized with respect to the total amount of MAPK1 in each sample. The bar graphs represent the mean 6 SEM of at least four separate experiments performed with four different patients. *P , 0.05, significant difference compared to the control.
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ml SFTPA1 results in a marked increase in the intensity of the immunoreactive PTGS2 band. Analysis of the time-course revealed that PTGS2 protein expression reached a maximum after 4 h of SFTPA1 treatment and was sustained at 6 h. Stimulation for 4 h with SFTPA1 induced a dose-dependent (5-20 lg/ml) expression of PTGS2 protein.
SFTPA1-Induced Formation of Filamentous-Actin Fibers
We evaluated the ability of SFTPA1 to induce actin stress fibers as an indicator of reorganization of the cytoskeleton in myometrial cells. Filamentous (F)-actin is the major microfilament of stress fibers. Exposure of quiescent myometrial cells to SFTPA1 (20 lg/ml) for 30 min resulted in an increase in the FITC-phalloidin staining intensity of F-actin compared to untreated cells (Fig. 7) . Pretreatment of the cells with the selective ROCK inhibitor, Y-27632 (10 lM, 45 min), markedly attenuated stress fiber formation induced by SFTPA1. To examine further whether SFTPA1-induced cytoskeleton reorganization was mediated by PRKC, myometrial cells were pretreated with the selective PRKC inhibitor, Ro 318220 (1 lM, 45 min) prior to SFTPA1 stimulation. Pretreatment with Ro 318220 blocked SFTPA1-induced increase in F-actin staining. Neither treatment with ROCK inhibitor nor PRKC inhibitor alone had an effect on actin reorganization.
DISCUSSION
The present study provides strong evidences that cultured human myometrial cells expressed functional SFTPA1 binding sites and respond to SFTPA1 to regulate the actin dynamic. Our findings suggest that this process involves activation of at least the transcription factor RELA and the signaling proteins associated with uterine contractions, namely MAPK1/3, PRKCZ, and PTGS2.
Our results show that SFTPA1 is expressed in the whole human term pregnant myometrium as well as in cultured human myometrial cells. Since our study was conducted on a culture system that retained most of the normal physiological properties that occur in vivo in a fully differentiated uterine smooth muscle (biochemical features and contractile properties) [23, 28] , the presence of immunoreactive SFTPA1 observed in our cell model may therefore be of physiological relevance. Ligand blot analysis with iodinated SFTPA1 consistently identified two SFTPA1 interacting proteins with molecular masses of 55 and 200 kDa in human myometrial cells. The SFTPA1 binding protein (at about 200 kDa) observed in myometrial cells may correspond to the 210-kDa SFTPA1 binding protein (SFTPA1R210) originally isolated from macrophages by Chroneos et al. [26] and described in alveolar type II cells [29] and lymphocytes [30] . This receptor reported in rat [15] and in human myometrial cells may correspond to SFTPA1R210, which was previously identified as a cell surface form of myosin XVIIIA acting as a highaffinity SFTPA1 receptor [31] . As reported in rat myometrium [15] , the second SFTPA1 binding protein (at about 55 kDa) was also found in human myometrial cells. This 55-kDa protein, like the 200-kDa protein, competed with SFTPA1 for binding to myometrial cells. In rat myometrium, LPS impaired the recognition of SFTPA1 by its binding sites and the addition of both LPS and SFTPA1 resulted in a less extended activation of MAPK1/3 compared with LPS or SFTPA1 alone [15] . Inhibition of LPS-induced NFkappaB activity by SFTPA1 has been suggested to occur via direct interaction of SFTPA1 with components of the LPS receptor complex, including lipopolysaccharide binding protein, CD14, TLR4, and LY96, but also by mechanisms independent of the LPS signaling pathway [19, 32, 33] . As previously reported [21] , we confirmed that the anti-TLR4 prevented LPS-induced nuclear translocation of RELA, but it failed to inhibit the SFTPA1-mediated nuclear translocation of RELA. These data suggest that SFTPA1 mediated its effect independently from TLR4 in human myometrial cells or that the SFTPA1 binding domain present in TLR4 remained available when anti-TLR4 antibodies were bound to TLR4 receptors [18] . These data also indicate that the SFTPA1 effects were not due to the presence of residual LPS contaminants (0.12 pg/lg SFTPA1) in our SFTPA1 preparations. However, the mechanism involved in the cross-talk between LPS and SFTPA1 remains to be determined in myometrium.
The present study also suggests that the SFTPA1 binding proteins might be functional receptors. Thus, binding of SFTPA1 to its receptors is associated with NFkappaB, MAPK, and PRKCZ activation. Unraveling the whole cascade of NFkappaB activation occurring after SFTPA1 treatment of myometrial cells remains to be determined, but the pathway is complex because of the spatiotemporal regulation of NFkappaB subunit composition reported in the human myometrium during pregnancy [34] . In addition to being required for NFkappaB activation in human myometrial cells [21] , PRKCZ plays a key role in uterine contraction at the end of pregnancy [35] . We observed a clear and rapid increase of PRKCZ in the membrane fraction after SFTPA1 treatment. Such PRKZ activation is consistent with findings in alveolar macrophages identifying PRKCZ as an essential upstream mediator of NFKBIA/NFkappaB regulation by SFTPA1 [36] . We also showed that SFTPA1 induces a rapid and transient activation of MAPK1/3 in human myometrial cells. Classically associated with growth and cell proliferation [37, 38] , activation of MAPK has also been implicated in the regulation of myometrial contractility [39] [40] [41] [42] . In humans, the end of pregnancy coincides with an upregulation of MAPK activity [43] . MAPKs are also known to phosphorylate caldesmon [44] as well as GJA1 connexin 43 in order to contribute to the modulation of gap junctions, an intercellular communication network that permits the uterus to develop contractions [45] . Activation of MAPK pathway has also been implicated in the induction of PTGS2 and consequent prostaglandin production [27, 46, 47] . To support this, we showed in myometrial cells in culture that prolonged treatment with SFTPA1 resulted in an increase in PTGS2 protein levels. However, an independent MAPK activation of PTGS2 expression has been recently reported in cultured human myometrial cells [48] . These authors demonstrated that PTGS2 transcription was dependent on the action of PRKCZ probably through direct stimulation of the RELA transactivation. In view of our data, it might be proposed that SFTPA1 regulates human myometrial functions at the end of pregnancy through a network of signaling pathways that needs to cooperate for the parturition process.
In line with this proposal, our data demonstrate that SFTPA1 influenced cytoskeleton organization. The actin cytoskeleton of the uterine smooth muscle cells is dynamically regulated by uterine contractile agents and is able to play a major role in the formation of stress fibers and focal adhesions, both of which have been shown to contribute to the initiation and the maintenance of uterine contractions [49] . Our study demonstrated that SFTPA1 induced stress fiber formation in myometrial cells via signaling pathways that required PRKC and ROCK activities. Treatment of myometrial cells with Ro-318220 led to an inhibition of stress fiber formation after SFTPA1 exposure, indicating that the activation of PRKC is essential. These data are consistent with previously published functional data from our laboratory demonstrating a crucial role for PRKC in myometrial contraction in pregnant women [35] . Moreover, we observed that pharmacological inhibition of ROCK resulted in a clear reduction of stress fiber formation induced by SFTPA1. In human myometrium, ROCK inhibition has been associated with reduction of uterotonic-induced myometrial contractions [50] [51] [52] . Cross-talk between PRKC and RHOA/ROCK pathways may be key signaling events for calcium sensitization of myofilaments. Studying the participation of alternative pathways or unraveling the temporal sequence of phosphorylation and activation cascades that may be activated by SFTPA1 remains a formidable task in human myometrial cells at the end of pregnancy. Because cytoskeleton reorganization is a pivotal process in cell motility, secretion, and contraction, it is likely that the direct effect of SFTPA1 observed in myometrial cells may have physiological consequences at the time of parturition.
We suggested that the mechanism of SFTPA1 signaling in human myometrial cells resembles the one we previously described in rat myometrial cells [15] but differs from that initially described in a mouse model. Thus, the early work by Condon et al. [8] showed that SFTPA1, described as a link between fetal lung development and timing of labor, promotes uterine infiltration by amniotic fluid macrophages and initiates the uterine inflammatory response leading to parturition. However, the puzzle appears to be more complex in human, especially because trafficking of fetal macrophages into the myometrium of women with labor at term does not seem to occur [10, 11] . The hypothesis of local actions of signaling factors originating from intrauterine and/or adjacent tissues in the control of uterine functions needs to be explored. Because SFTPA1 AND HUMAN MYOMETRIAL CELLS SFTPA1 has already been reported to be present in human fetal membranes [53] [54] [55] , it remains to be determined whether the fetal membranes may represent an additional source of SFTPA1 at the end of pregnancy.
In conclusion, we have shown that cultured human myometrial cells are endowed with functional SFTPA1 binding sites and that SFTPA1 triggers signaling pathways leading to PRKCZ, MAPK1/3, and RELA activation, PTGS2 induction, and cytoskeleton reorganization. Activation of this array of cellular signaling events may be a prerequisite for the myometrium to develop contractile activity at the end of pregnancy. However, it cannot be ruled out that SFTPA1 may also modulate the expression of other members of the ''cassette'' of contraction-associated proteins known to be linked to the process of parturition, including GJA1, oxytocin receptor, ion channels, prostaglandin receptor, and others. Building a hierarchical vision of the signaling pathways that are activated during normal (or pathologic) pregnancy will be a challenge for the future.
